Plus   Neg

Stock Alert: Translate Bio

Shares of a clinical-stage messenger RNA (mRNA) therapeutics company, Translate Bio, Inc. (TBIO) gapped up nearly 12% at $11.48 Friday morning after the company announced that French pharmaceutical giant Sanofi is collaborating with Translate Bio to develop a novel mRNA vaccine for COVID-19.

TBIO is currently trading at $10.70, up 4.39%. It has traded in the range of$6.80- $14.34 in the past 52-weeks.

Translate Bio has begun to produce multiple mRNA constructs and will use its mRNA platform to discover, design and manufacture SARS-CoV-2 vaccine candidates.

The shares of Translate Bio have been increasing from February end after the FDA has granted Fast Track designation for its drug candidate, MRT5005 for the treatment of cystic fibrosis (CF). It has gained nearly 45% since then.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
Follow RTT